Methylomic deep sequencing of ovarian cancer reveals diagnostic and prognostic signatures

2013 Annual Meeting of the Taiwan Genomic Medicine and Biomarker Society Symposium on Clinical Application of Genomic Medicine

Research output: Contribution to journalArticle

Abstract

The heterogeneity of ovarian cancer requires biomarkers for personalized medicine. DNA methylation aberration is a hallmark of cancer. The attempt of using DNA methylation as biomarkers for prognosis prediction is appealing. Methylomic analysis using next generation sequencing technology has never been applied in ovarian cancer research. The present study for the first time is to explore the methylomics of ovarian cancer using this cutting edge technology.
Original languageTraditional Chinese
Pages (from-to)125
Number of pages1
JournalBiomarkers and Genomic Medicine
Volume5
Issue number3
DOIs
Publication statusPublished - Sep 2013
Externally publishedYes

Cite this

@article{757b0993bc7b4f078a7dd03a60de11fb,
title = "Methylomic deep sequencing of ovarian cancer reveals diagnostic and prognostic signatures: 2013 Annual Meeting of the Taiwan Genomic Medicine and Biomarker Society Symposium on Clinical Application of Genomic Medicine",
abstract = "The heterogeneity of ovarian cancer requires biomarkers for personalized medicine. DNA methylation aberration is a hallmark of cancer. The attempt of using DNA methylation as biomarkers for prognosis prediction is appealing. Methylomic analysis using next generation sequencing technology has never been applied in ovarian cancer research. The present study for the first time is to explore the methylomics of ovarian cancer using this cutting edge technology.",
author = "Rui-Lan Huang and Wang, {Hui Chen} and Hung-Cheng Lai",
year = "2013",
month = "9",
doi = "10.1016/j.bgm.2013.08.022",
language = "繁體中文",
volume = "5",
pages = "125",
journal = "Genomic Medicine, Biomarkers, and Health Sciences",
issn = "2214-0247",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Methylomic deep sequencing of ovarian cancer reveals diagnostic and prognostic signatures

T2 - 2013 Annual Meeting of the Taiwan Genomic Medicine and Biomarker Society Symposium on Clinical Application of Genomic Medicine

AU - Huang, Rui-Lan

AU - Wang, Hui Chen

AU - Lai, Hung-Cheng

PY - 2013/9

Y1 - 2013/9

N2 - The heterogeneity of ovarian cancer requires biomarkers for personalized medicine. DNA methylation aberration is a hallmark of cancer. The attempt of using DNA methylation as biomarkers for prognosis prediction is appealing. Methylomic analysis using next generation sequencing technology has never been applied in ovarian cancer research. The present study for the first time is to explore the methylomics of ovarian cancer using this cutting edge technology.

AB - The heterogeneity of ovarian cancer requires biomarkers for personalized medicine. DNA methylation aberration is a hallmark of cancer. The attempt of using DNA methylation as biomarkers for prognosis prediction is appealing. Methylomic analysis using next generation sequencing technology has never been applied in ovarian cancer research. The present study for the first time is to explore the methylomics of ovarian cancer using this cutting edge technology.

U2 - 10.1016/j.bgm.2013.08.022

DO - 10.1016/j.bgm.2013.08.022

M3 - 文章

VL - 5

SP - 125

JO - Genomic Medicine, Biomarkers, and Health Sciences

JF - Genomic Medicine, Biomarkers, and Health Sciences

SN - 2214-0247

IS - 3

ER -